04IC.F · InVivo Therapeutics Holdings Corp

-

Please sign in to comment on 04IC.F

1 Comment

Admin

3 years, 7 months ago

InVivo Therapeutics Holdings Corp is currently in a long term downtrend where the price is trading 26.5% below its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

InVivo Therapeutics Holdings Corp's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has increased by 35.0% to $-2M since the same quarter in the previous year.

Finally, its free cash flow fell by 2.4% to $-2M since the same quarter in the previous year.

Based on the above factors, InVivo Therapeutics Holdings Corp gets an overall score of 2/5.

ISIN	None
Industry	Biotechnology
Sector	Healthcare
CurrencyCode	EUR
Exchange	F

Beta	1.07
Dividend Yield	0.0%
Target Price	None
PE Ratio	None
Market Cap	7M

ABOUT

InVivo Therapeutics Holdings Corp

InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord to treat acute SCI. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.

04IC.F · InVivo Therapeutics Holdings Corp

-

InVivo Therapeutics Holdings Corp

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest InVivo Therapeutics Holdings Corp using a moving average strategy